Clinical trials: Pediatric Overweight
Bardet-Biedl Syndrome, POMC Deficiency Obesity
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
This is a phase 3 open-label, clinical study to evaluate the efficacy, safety and tolerability of setmelanotide over 1 year of treatment, in pediatric participants aged 2 to <6 years with obesity due to either biallelic variants…
- Conditions
- Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity
- Trial name
- NCT04966741
- Testing
- Setmelanotide
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 12 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity.
- Trial name
- NCT05696847
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Adolescent Obesity, Obesity in Adolescence
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
This study is being conducted to assess weight loss efficacy, as determined by changes in body mass index (BMI), and safety of VI-0521 (Qsymia®) or placebo, taken for 56 weeks accompanied by a lifestyle modification program in…
- Conditions
- Adolescent Obesity, Obesity in Adolescence, Adolescent Overweight
- Trial name
- NCT03922945
- Testing
- VI-0521 oral capsule, Lifestyle Modification
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- VIVUS LLC
Pediatric Obesity, Childhood Obesity
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
The primary objective of this study is to describe the pharmacokinetic profiles of VI-0521 in obese adolescents.
- Trial name
- NCT02714062
- Testing
- VI-0521 Mid Dose, VI-0521 Top Dose
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- VIVUS LLC